Why AstraZeneca plc Is A Great Share For Novice Investors

Here’s why you should consider buying AstraZeneca plc (LON: AZN) shares.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

After I spent some time last week telling you why GlaxoSmithKline is my pick of the FTSE’s pharmaceuticals sector for novices, you might expect me to turn my nose up at AstraZeneca (LSE: AZN) (NYSE: AZN) today.

But no, I’m going to do the opposite, and tell you why I like AstraZeneca as well.

AstraZeneca may only be a little over half the size of GlaxoSmithKline in terms of market capitalisation (£40bn compared to £77bn), and only enjoyed around 65% of its 2012 annual turnover at £17bn. But it’s still the 14th biggest company listed in London and still easily enjoys the “big pharma” clout when a bit of financial muscle is needed — for acquisitions, to get through tough patches and work towards the long term, and such things.

Over the past couple of years, I do think AstraZeneca has been slower than some of the competition to embrace the moves towards biotechnology and to decide what its long-term strategy is to be, and that’s part of the reason I plumped for Glaxo for the Fool’s Beginners’ Portfolio in June last year.

New broom

But since then I’ve been impressed by new chief executive Pascal Soriot, who took the helm in October 2012 and immediately set about focusing on the company’s core strengths. As recently as 1 August this year, in the firm’s first-half results release, Mr Soriot said: “We have made real progress in the second quarter against our strategic priorities […]. We continue to invest in distinctive science, our pipeline projects, products and key markets and our five key growth platforms delivered a double-digit increase in revenue contribution.

I don’t want to get too concerned about short-term results and valuations, because that’s not what this series of articles is about, and at the halfway stage AstraZeneca’s profit figures were down as expected — whether you think a share on a forward P/E of 10 and offering a likely dividend of around 5.5% is cheap at the moment is up to you.

But what I think recent developments do show is that a company like AstraZeneca has the ability to respond in a careful and measured way to changes, like losses of patent protection and increased competition from generic drugs, without any need for panic.

Three years of falling earnings, which is what we should have by the time 2014 is out, could well lead to a share price slump for smaller companies in this kind of business — and in some other sectors, the sound of the crash would most likely be deafening.

Minimise the downside

But since the end of 2011, the last year AstraZeneca reported a rise in EPS, we’ve actually seen the shares gain 8% to today’s 3,214p. Sure, that’s not great, but it does suggest the downside is limited even during relatively tough times — and shareholders did get an extra 6% in dividends at the end of 2012.

We’re starting to see some positive-looking acquisitions and collaborations, too, so a relatively weak performance on that score over the short term is no great problem in the long term, either.

And I think these points help emphasis something that novices are wont to overlook — when you’re starting out, you should first be looking to reduce your risk of losses. And to do that, you’ll learn a lot more about a company’s risk when it’s going through a weaker spell than when it’s flying high.

And to me, AstraZeneca is looking good.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Alan does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »